MedTrace Logo

A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

NCT04214951 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-10-20

Study results available
· View outcomes & findings →

Summary

Thrombopoietin Receptor Agonists (TPO-ra) are novel treatments for patients with refractory Primary Immune Thrombocytopenia (ITP). Rh-TPO and eltrombopag increase the number of platelets through different mechanism. If there is cross-resistance between 2 drugs for the treatment of adult ITP is still no answer. The purpose of this study is to investigate the efficacy and safety of switching eltrombopag and Rh-TPO in adults with ITP.

Conditions

  • Corticosteroid-resistant or Relapsed ITP

Interventions

DRUG

Eltrombopag

Patients will be given eltrombopag 50mg once daily for 6 weeks.

DRUG

Recombinant human thrombopoietin (rh-TPO)

Patients will be given rh-TPO 300 U/kg once daily for 21 days.

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiao Hui Zhang, MD · Peking University People's Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-08-01
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04214951 on ClinicalTrials.gov